CRISPR: How Gene Editing Works
Gene editing sounds like science fiction, but the tool was stolen from bacteria. A short guide RNA — a 20-letter search string — leads the protein Cas9 to one exact spot in three billion letters of DNA, checks for a tiny nearby signal called the PAM, and cuts both strands. Then the cell’s own repair crew takes over, and that is where the editing really happens: a sloppy patch can switch a gene off, or a supplied template can paste in a corrected sequence. Press play and watch Cas9 hunt, bind and cut — then break it on purpose and watch it cut the wrong place.
Try this: let it run once on Target a gene, then switch to Correct a mutation and watch a green template paste the fix — then choose Off-target and see Cas9 cut a near-match by mistake (the real-world risk).
Live editing readout
What's happening
REAL: the guide RNA spacer is ~20 nucleotides; SpCas9 requires a 5′-NGG-3′ PAM and cuts about 3 bp upstream of it; NHEJ knockouts vs template (HDR) corrections are the two real repair routes. ILLUSTRATIVE: the ladder size, timing, and the “off-target risk” percentage — real off-target rates depend entirely on the guide and the Cas variant.
The Science in Plain Language
1. It was borrowed from a bacterial immune system
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats — a mouthful that describes a filing cabinet inside bacteria. When a virus attacks a bacterium and the cell survives, it snips out a small piece of the virus’s DNA and files it away between these repeats, like keeping a mugshot. If that virus ever returns, the bacterium transcribes the stored snippet into a short RNA, hands it to a cutting protein (a Cas, for “CRISPR-associated” enzyme), and destroys the invader’s DNA on sight. It is a real, ancient adaptive immune system in single-celled life. In 2012, Emmanuelle Charpentier and Jennifer Doudna showed the machinery could be reprogrammed to cut any chosen DNA sequence — work that won them the 2020 Nobel Prize in Chemistry.
2. Two parts: a guide RNA and a pair of scissors
The tool you see in the animation has just two working pieces. The guide RNA is a short RNA molecule whose business end is a roughly 20-nucleotide “spacer” — a 20-letter search string you can type to match almost any gene. In nature this actually comes as two separate RNAs (a crRNA that carries the address and a tracrRNA that grips Cas9); the 2012 breakthrough fused them into a single, easy-to-program molecule called a single-guide RNA (sgRNA). The scissors are Cas9, a large protein of about 1,360 amino acids, most commonly taken from Streptococcus pyogenes (SpCas9). Load the guide into Cas9 and you have a programmable seeking missile: the guide holds the address, and Cas9 does the cutting. Change the 20 letters and you change the target — that reprogrammability is the whole revolution.
3. The PAM: a two-letter password that stops CRISPR eating itself
Cas9 will not cut on the guide match alone. Right next to the target it must also find a tiny signal called the PAM (Protospacer Adjacent Motif). For SpCas9 the PAM is 5′-NGG-3′ — any base, then two G’s. This is not a footnote; it is genius. The snippets a bacterium files away in its own CRISPR array do not carry a PAM, but the matching viral DNA does — so the PAM check is how the immune system tells “the invader” from “my own memory of the invader” and avoids cutting its own genome. In the lab it simply means every editable site must sit beside an NGG, which is common but not universal — one reason scientists have hunted for other Cas proteins. A cousin called Cas12a (Cpf1), for example, reads a T-rich PAM and leaves staggered “sticky” ends instead of a blunt cut, which expands the range of sequences you can reach.
4. The cut: both strands, in about a millisecond of biology
Once the guide base-pairs to the target and the PAM checks out, Cas9 clamps down and two internal blades — the HNH and RuvC domains — each slice one strand of the double helix, roughly 3 base pairs upstream of the PAM. The result is a clean double-strand break: the DNA is severed straight across. On its own, a cut edits nothing. The break is a demolition, not a renovation — the actual editing happens in what the cell does next.
5. Two repairs: knock a gene out, or paste a correction in
A double-strand break is an emergency, so the cell rushes to fix it, and there are two main routes. The fast, sloppy route is NHEJ (non-homologous end joining): it glues the ends back together but often drops or adds a few letters. That small scar usually scrambles the gene’s reading frame and switches the gene off — exactly what you want when a gene is harmful. The precise route is HDR (homology-directed repair): if scientists also supply a DNA template carrying the correct sequence, the cell can copy it in and fix the mutation. In the animation, “Knock out” shows the messy NHEJ scar; “Correct a mutation” shows a green template pasting the healthy sequence.
6. This is already curing people
This is not a someday technology. In late 2023, regulators in the UK and then the US FDA approved Casgevy (exagamglogene autotemcel) — the first approved CRISPR medicine — for sickle cell disease and transfusion-dependent beta-thalassemia. Doctors remove a patient’s own blood-forming stem cells, edit them in the lab, and infuse them back. Here is the clever part, and a common point of confusion: Casgevy does not repair the sickle mutation in the HBB gene directly. Instead it disrupts a switch called BCL11A that normally shuts off fetal hemoglobin after birth. Turn that switch off and the patient’s red cells start making fetal hemoglobin again, which does not sickle. It is a CRISPR knockout used to reawaken a healthy backup gene — and in trials it freed most patients from the agonizing pain crises of sickle cell. Because the editing is done on cells outside the body (“ex vivo”) and then reinfused, doctors can check the edited cells before giving them back.
The next frontier is editing genes inside the body (“in vivo”). An experimental therapy for transthyretin (ATTR) amyloidosis packages the CRISPR machinery into tiny fatty bubbles called lipid nanoparticles, injects them into the bloodstream, and lets the liver take them up and switch off the disease-causing TTR gene — the first time gene editing has been performed directly in a living person’s organ rather than in a dish. Getting the tool safely to the right tissue, and only that tissue, is now one of the hardest problems in the field.
7. Newer editors change a single letter without a full cut
Double-strand breaks are blunt, and NHEJ is unpredictable, so a newer generation avoids the full cut. Base editors (from David Liu’s lab, 2016) fasten a chemical “pencil’s eraser” onto a disabled Cas9 that only nicks one strand, letting it change one DNA letter into another — a C•G pair into T•A, or an A•T pair into G•C — without ever severing the helix. Prime editing (2019) goes further: it fuses Cas9 to a reverse transcriptase and uses an extended guide that also carries the new text, working like a molecular “find and replace.” These tools can, in principle, fix many single-letter mutations more cleanly than a cut-and-repair edit.
8. The honest cautions: off-target cuts and editing embryos
Two worries are real, and this page shows the first one. Because the guide tolerates a few mismatched letters — especially far from the PAM — Cas9 can sometimes cut a near-match “off-target” site elsewhere in the genome, as in the last scenario. Scientists reduce this with more careful guide design and high-fidelity Cas9 variants (such as eSpCas9 and HiFi Cas9), and by sequencing to check. The second worry is ethical: every approved therapy so far edits somatic cells — the patient’s own tissue — so the change dies with them and is not inherited. Editing a sperm, egg, or embryo would be heritable, passed to all future generations. In 2018 a scientist did exactly that with human embryos; it was condemned worldwide and led to his imprisonment. Heritable germline editing remains broadly prohibited.
9. The myth worth correcting
The popular image is a menu of “designer babies” — order blue eyes, tall, a genius. That is not how the science works. CRISPR reliably edits one gene at a time, and the traits people fantasize about — intelligence, height, personality — are shaped by thousands of genes plus environment, with no single letter to flip. What CRISPR is genuinely good at is the opposite: precise fixes to single-gene diseases such as sickle cell, beta-thalassemia, and certain inherited blindness and liver disorders. The truthful headline is narrower and, honestly, more remarkable — not building people to order, but repairing one broken instruction in the cells of someone who is already sick.